Jazz Pharmaceuticals Acquires Redx Pharma’s Pre-clinical Pan-RAF Inhibitor Program for RAF and RAS Mutant Tumors

Shots:

• Redx to receive $3.5M up front, up to $203M as milestone & royalties on sales and will be responsible for pre-clinical activities of the program under a separate collaboration agreement with Jazz. Jazz to get rights to develop & commercialize Pan-RAF program and is responsible for its regulatory activities
• The focus of the acquisition is to robust Jazz’s R&D portfolio of early-stage hematology/oncology therapies with the advancement of Redx’s pan-RAF inhibitor program, a precision oncology therapies
• The preclinical results of the pan-RAF program demonstrated in-vivo efficacy in a B-RAFV600E mutant colorectal cancer xenograft model as monothx. with promising activity in RAS-mutated cancer

Click here to read full press release/ article | Ref: Jazz Pharmaceutical | Image: GMP News